Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Immune Sandwich Regimen vs Full-Course Immunotherapy in Locally Advanced Nasopharyngeal Carcinoma
NCT07706985Phase 3Recruiting
- Sponsor
- Sun Yat-sen University
- Start
- Jul 2026
- Primary completion
- Jul 2030
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of toripalimab and nimotuzumab in nasopharyngeal carcinoma (NPC) (2 arms), sponsored by Sun Yat-sen University. Primary endpoint: Event-Free Survival at 3 years. Started Jul 2026; status: recruiting.
02
Drugs
toripalimabnimotuzumab
03
Conditions
nasopharyngeal carcinoma (NPC)
Beyond the preview
Go deeper on NCT07706985.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07706985.